TrialsgrambetaRCTs are beautiful

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease

This guideline cites 8 of the 199 landmark trials in our Cardiology register.

The 2020 ACC/AHA valve guideline builds its aortic-stenosis pathway on age rather than on surgical risk score: surgical replacement is preferred below 65 years, transcatheter replacement above 80, and between 65 and 80 the choice is shared with the patient. That is a markedly more conservative age line than the ESC/EACTS 2025 guideline, which makes TAVI a reasonable option from 70 years and reframes the whole decision as lifetime management. In mitral regurgitation the guideline separates primary (degenerative) from secondary disease and confines transcatheter edge-to-edge repair to the COAPT phenotype. Trials that appeared after 2020 — the early-intervention and low-risk-TAVI studies now driving the European position — are listed separately below.

Aortic stenosis: TAVI vs. SAVR4

  • 2019PARTNER 3 Core⁠Cardiology · Structural · TAVRIn 1,000 patients with severe AS at low surgical risk, TAVR with the SAPIEN 3 valve reduced death, stroke or rehospitalisation at one year versus surgical AVR.HR 0.54Read →
  • 2019Evolut Low Risk⁠Cardiology · Structural · TAVRIn 1,468 patients with severe AS at low surgical risk, TAVR with a self-expanding valve was non-inferior to surgical aortic-valve replacement for death or disabling stroke at 2 years.5.3% vs 6.7%Read →
  • 2016PARTNER 2A⁠Cardiology · Structural · TAVRIn 2,032 intermediate-risk patients with severe aortic stenosis, transcatheter aortic-valve replacement was non-inferior for 2-year death or disabling stroke compared with surgical aortic-valve replacement.HR 0.8995% CI 0.73-1.09Read →
  • 2010PARTNER 1B Core⁠Cardiology · Structural · TAVRIn 358 patients with severe AS deemed inoperable, transcatheter aortic-valve replacement reduced all-cause mortality at 1 year compared with medical therapy.HR 0.55Read →

Mitral regurgitation: transcatheter repair3

  • 2018COAPT Core⁠Cardiology · Structural · MitralIn 614 patients with HF and severe secondary mitral regurgitation, MitraClip plus GDMT reduced HF hospitalisation and all-cause mortality compared with GDMT alone.HR 0.53Read →
  • 2018MITRA-FR⁠Cardiology · Structural · MitralIn 304 patients with heart failure and severe secondary mitral regurgitation, transcatheter mitral repair did not reduce death or heart-failure hospitalisation compared with medical therapy alone.OR 1.1695% CI 0.73-1.84Read →
  • 2011EVEREST II⁠Cardiology · Structural · MitraClipIn 279 patients with grade 3+/4+ mitral regurgitation, percutaneous MitraClip repair was less effective at reducing death, mitral surgery, or residual MR at 12 months but safer than mitral valve surgery.55% vs 73%Read →

Prosthetic valves: anticoagulation1

  • 2013RE-ALIGN⁠Cardiology · Structural · AnticoagulationIn 252 patients with a mechanical aortic or mitral valve, dabigatran led to more thromboembolic events and major bleeding compared with warfarin.5% vs 0%Read →

Published since the guideline5

  • 2025EARLY TAVR⁠Cardiology · Structural · TAVRIn 901 patients with asymptomatic severe aortic stenosis, early TAVR reduced death, stroke or unplanned cardiovascular hospitalisation compared with clinical surveillance.HR 0.5Read →
  • 2024NOTION-2⁠Cardiology · Structural · TAVRIn 370 younger, low-risk patients (≤75 years) with severe aortic stenosis, transcatheter aortic-valve implantation was not shown non-inferior for 1-year death, stroke, or rehospitalisation compared with surgical aortic-valve replacement.10.2% vs 7.1%Read →
  • 2023TRILUMINATE⁠Cardiology · Structural · TricuspidIn 350 patients with severe symptomatic tricuspid regurgitation, transcatheter tricuspid repair improved quality of life compared with medical therapy.WR 1.48Read →
  • 2022AVATAR⁠Cardiology · Structural · early AVRIn 157 patients with asymptomatic severe aortic stenosis, early aortic valve replacement reduced death, MI, stroke, or HF hospitalisation compared with watchful waiting.HR 0.4695% CI 0.23-0.90Read →
  • 2022PROTECTED TAVR⁠Cardiology · Structural · cerebral embolic protectionIn 3,000 patients undergoing transcatheter aortic-valve replacement, the Sentinel cerebral embolic protection device did not reduce periprocedural stroke compared with no embolic protection.2.3% vs 2.9%Read →

Cited landmark trials not yet in the register4

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2011PARTNER 1A

    TAVI versus surgery in high-risk aortic stenosis — non-inferior at one year.

  • 2014CoreValve US Pivotal High Risk

    Self-expanding TAVI was superior to surgery for survival in high-risk patients.

  • 2017SURTAVI

    Self-expanding TAVI versus surgery in intermediate surgical risk.

  • 2020RECOVERY

    Early surgery versus conservative care in asymptomatic very severe aortic stenosis.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.